4.13
Schlusskurs vom Vortag:
$4.14
Offen:
$4.07
24-Stunden-Volumen:
449.12K
Relative Volume:
0.52
Marktkapitalisierung:
$396.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-238.77M
KGV:
-0.1541
EPS:
-26.808
Netto-Cashflow:
$-216.62M
1W Leistung:
+6.44%
1M Leistung:
+36.75%
6M Leistung:
-44.79%
1J Leistung:
-67.45%
Alumis Inc Stock (ALMS) Company Profile
Firmenname
Alumis Inc
Sektor
Branche
Telefon
650-231-6625
Adresse
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie ALMS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ALMS
Alumis Inc
|
4.13 | 427.20M | 0 | -238.77M | -216.62M | -26.81 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-25 | Eingeleitet | Wells Fargo | Overweight |
2025-06-10 | Fortgesetzt | Guggenheim | Buy |
2025-01-30 | Eingeleitet | Oppenheimer | Outperform |
2024-10-31 | Eingeleitet | Robert W. Baird | Outperform |
2024-10-17 | Eingeleitet | H.C. Wainwright | Buy |
2024-07-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
2024-07-23 | Eingeleitet | Guggenheim | Buy |
2024-07-23 | Eingeleitet | Leerink Partners | Outperform |
2024-07-23 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Alumis Inc Aktie (ALMS) Neueste Nachrichten
How does Alumis Inc. compare to its industry peersDaily Trading Outlook With Proven Results - jammulinksnews.com
When is Alumis Inc. stock expected to show significant growthBreakout Stocks Updates With Proven Results - jammulinksnews.com
What institutional investors are buying Alumis Inc. stockTop Growth Planner For Every Investor - jammulinksnews.com
Is Alumis Inc. a growth stock or a value stockStock Strategy Tracker For Every Investor - jammulinksnews.com
What makes Alumis Inc. stock price move sharplyAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it
Alumis (ALMS) Merges with ACELYRIN - Insider Monkey
What is the risk reward ratio of investing in Alumis Inc. stockHarness the power of proven investment plans - jammulinksnews.com
Alumis Inc.: Promising Pipeline and Strategic Advancements Justify Buy Rating - TipRanks
How strong is Alumis Inc. company’s balance sheetTop Growth Entry Points With Low Risk - jammulinksnews.com
What markets is Alumis Inc. expanding into Is ELPW stock a good long term investment optionMaximize returns with smart investment plans - jammulinksnews.com
How does Alumis Inc. generate profit in a changing economyInvest confidently with professional advice - jammulinksnews.com
What is the dividend policy of Alumis Inc. stockUnlock your trading potential today - jammulinksnews.com
What are analysts’ price targets for Alumis Inc. in the next 12 monthsHigh-performance investment picks - jammulinksnews.com
Is Alumis Inc. stock a good hedge against inflationBest Stocks for Capital Safety - metal.it
What analysts say about Alumis Inc. stockAccelerated capital growth - PrintWeekIndia
Alumis Inc. Stock Analysis and ForecastFree Investment Community - PrintWeekIndia
Alumis Inc.: Buy Rating Affirmed Amid Promising ESK-001 Developments and Strong Financial Projections - TipRanks
Alumis initiated with an Overweight at Wells Fargo - TipRanks
What institutions are buying Alumis Inc. stock nowExplosive wealth accumulation - jammulinksnews.com
Is Alumis Inc. a good long term investmentSuperior capital gains - PrintWeekIndia
What drives Alumis Inc. stock priceUnbelievable profit margins - PrintWeekIndia
Alumis completes enrollment in lupus treatment phase 2b trial By Investing.com - Investing.com India
Alumis completes enrollment in lupus treatment phase 2b trial - Investing.com
Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus - The Manila Times
Alumis Inc. Completes Patient Enrollment in LUMUS Phase 2b Trial of ESK-001 for Systemic Lupus Erythematosus, Topline Data Expected Q3 2026 - Nasdaq
Major Breakthrough: 408 Patients Enrolled in Advanced Trial for New Oral Lupus Treatment - Stock Titan
Finanzdaten der Alumis Inc-Aktie (ALMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alumis Inc-Aktie (ALMS) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Tananbaum James B. | Director |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
Foresite Labs, LLC | 10% Owner |
May 02 '25 |
Buy |
4.62 |
25,000 |
115,500 |
4,227,670 |
Foresite Labs, LLC | 10% Owner |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
Foresite Capital Management VI | 10% Owner |
May 02 '25 |
Buy |
4.62 |
25,000 |
115,500 |
4,227,670 |
Foresite Capital Management VI | 10% Owner |
May 06 '25 |
Buy |
4.34 |
20,000 |
86,800 |
4,247,670 |
AKKARAJU SRINIVAS | Director |
May 05 '25 |
Buy |
4.67 |
160,370 |
749,676 |
3,586,788 |
AKKARAJU SRINIVAS | Director |
May 02 '25 |
Buy |
4.55 |
159,920 |
727,636 |
3,426,418 |
Colowick Alan | Director |
Apr 01 '25 |
Buy |
6.97 |
16,104 |
112,309 |
16,104 |
Colowick Alan | Director |
Apr 02 '25 |
Buy |
7.49 |
2,300 |
17,235 |
18,404 |
Babler Martin | President, CEO and Chairman |
Apr 01 '25 |
Buy |
6.44 |
15,650 |
100,733 |
106,454 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):